Document is current
Any future updates will be listed below
-
Authors
Marín-Medina, Daniel S. https://orcid.org/0000-0002-9077-6309
Zambrano, Joselyn Miño https://orcid.org/0000-0002-7483-3481
Espay, Alberto J. https://orcid.org/0000-0002-3389-136X
Merello, Marcelo https://orcid.org/0000-0001-6898-7823
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (Edmond J. Safra Fellowship in Movement Disorders))
- License Information
-
More Information
Article History
Received: 20 February 2026
Revised: 25 March 2026
Accepted: 28 March 2026
First Online: 8 April 2026
Declarations
:
: AJE has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acorda, Abbvie, Bial, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma; Data Safety Monitoring Board (chair) of AskBio; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies” with which he cofounded REGAIN Therapeutics to fund preclinical studies. He has no financial relationship with the company and has relinquished the right to any personal income from future treatments. Dr. Espay owns no stock in any pharmaceutical company with which he has a scientific advisory relationship. The authors declare that they have no conflict of interest. All other authors declare that they have no conflict of interest.
: The manuscript does not contain clinical studies or patient data.
